The Evolving Future of PCSK9 Inhibitors

The Evolving Future of PCSK9 Inhibitors

Variants in proprotein convertase subtilisin/kexin type 9 (PCSK9) provide insights into mechanisms regulating low-density lipoprotein (LDL) levels. Human monoclonal antibodies that target PCSK9 lower LDL cholesterol (LDL-C) levels by 55% to 72% in different high-risk patient groups. Clinical trials...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 2018-07, Vol.72 (3), p.314-329
Hauptverfasser: Rosenson, Robert S., Hegele, Robert A., Fazio, Sergio, Cannon, Christopher P.
Format: Artikel
Sprache:eng
Schlagworte:
acute coronary syndrome
Acute coronary syndromes
Arteriosclerosis
Atherosclerosis
atherosclerotic cardiovascular disease
Cardiology
Cardiovascular diseases
Cholesterol
Clinical outcomes
Clinical trials
Coronary artery
Coronary artery disease
Diabetes
Disease prevention
Genes
Heart diseases
Inhibitors
Kexin
Low density lipoprotein
Medical research
Monoclonal antibodies
Mutation
Patients
peripheral arterial disease
Proprotein convertases
Risk groups
Statins
Subtilisin
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Variants in proprotein convertase subtilisin/kexin type 9 (PCSK9) provide insights into mechanisms regulating low-density lipoprotein (LDL) levels. Human monoclonal antibodies that target PCSK9 lower LDL cholesterol (LDL-C) levels by 55% to 72% in different high-risk patient groups. Clinical trials with PCSK9 inhibitors have demonstrated reductions in atherosclerotic cardiovascular disease events, particularly in patients with recent acute coronary syndrome, multivessel coronary artery disease, or peripheral arterial disease. Commonly observed profound reductions in LDL-C to levels 
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2018.04.054